Home » Stocks » BCYC

Bicycle Therapeutics PLC (BCYC)

Stock Price: $29.75 USD -0.61 (-2.01%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $29.71 -0.04 (-0.13%) May 13, 4:59 PM
Market Cap 729.80M
Revenue (ttm) 11.07M
Net Income (ttm) -55.88M
Shares Out 24.08M
EPS (ttm) -4.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $29.75
Previous Close $30.36
Change ($) -0.61
Change (%) -2.01%
Day's Open 30.59
Day's Range 29.09 - 30.73
Day's Volume 36,058
52-Week Range 14.00 - 33.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

1 week ago - Business Wire

Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a c...

1 month ago - GlobeNewsWire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

1 month ago - Business Wire

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

1 month ago - Zacks Investment Research

Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year

1 month ago - GlobeNewsWire

Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today ...

1 month ago - GlobeNewsWire

Leuven, BE, Boston, MA, US – March 31st, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, today a...

1 month ago - GlobeNewsWire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

1 month ago - Business Wire

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

1 month ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 months ago - Business Wire

Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a cli...

2 months ago - GlobeNewsWire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

3 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

5 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its propri...

5 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

7 months ago - Business Wire

Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed this week his firm upped its stake in Bicycle Therapeutics PLC (NASDAQ:BCYC) by 175.4%.

7 months ago - GuruFocus

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

7 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

9 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

9 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

9 months ago - Business Wire

Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

This biotech company was founded by a Nobel laureate.

11 months ago - The Motley Fool

Clinical trial successes could send shares of these drugmakers screaming higher.

Other stocks mentioned: BTAI, IGMS
1 year ago - The Motley Fool

Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Is (BCYC) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

These five biotech stocks could post life-changing gains for early-bird investors.

Other stocks mentioned: CPRX, FOLD, INO, NVAX
1 year ago - The Motley Fool

Top Ranked Momentum Stocks to Buy for March 16th

Other stocks mentioned: CODX
1 year ago - Zacks Investment Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the nea...

1 year ago - Zacks Investment Research

Is (BCYC) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for March 13th

Other stocks mentioned: GSX, RCUS, VIRT
1 year ago - Zacks Investment Research

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCEL, BMY, CPRX, CRNX ...
1 year ago - The Motley Fool

Bicycle's Technology Uses 2-Step Approach To Treating Cancer And Many Other Diseases

1 year ago - Seeking Alpha

These two clinical-stage biotechs could yield exponential returns for early investors.

Other stocks mentioned: NVAX
1 year ago - The Motley Fool

These top growth stocks could dramatically improve your financial wellbeing.

Other stocks mentioned: ADAP, AMRN, APHA, NVAX, PBYI
1 year ago - The Motley Fool

Bicycle Therapeutics: Early Stage Platform Technology Play With Multiple Upside Drivers

1 year ago - Seeking Alpha

Bicycle Therapeutics: A Disruptive New Entrant To The Vast Targeted Cancer Treatment Space

1 year ago - Seeking Alpha

Bicycle peptides are fully synthetic short peptides constrained to form two loops using a chemical connector compound known as a scaffold, which stabilizes their structural geometry.

1 year ago - Seeking Alpha

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune c... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 2019
CEO
Kevin Lee
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
BCYC
Full Company Profile

Financial Performance

In 2020, BCYC's revenue was $10.39 million, a decrease of -24.72% compared to the previous year's $13.80 million. Losses were -$51.01 million, 66.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is 41.33, which is an increase of 38.92% from the latest price.

Price Target
$41.33
(38.92% upside)
Analyst Consensus: Buy